To obtain AMA PRA Category 1 Credit™ for this activity, complete the CME Post Test and activity evaluation online at http://tinyurl.com/AMDLongTerm . Upon successful completion of the post test and activity evaluation, you will be able to generate an instant certificate of credit.

See detailed instructions at Instructions to Receive Credit on page 2.

1. How often should patients doing home monitoring for conversion to neovascular AMD with the PHP device be encouraged to use it?
   A. Daily
   B. Weekly
   C. Every 2 weeks
   D. Monthly
2. Which of the following imaging modalities is most useful for diagnosing PCV?
   A. FAF
   B. ICGA
   C. OCT angiography
   D. Red-free photography
3. Published efficacy and safety data from studies of patients with neovascular AMD indicate that, compared with other anti-VEGF agents, aflibercept results in the following outcome.
   A. Dries the retina better
   B. Has a lower risk of stroke
   C. Is associated with greater improvement in VA
   D. Should be the agent of choice when treating with an as-needed regimen
4. Which of the following outcomes is shown in efficacy data from studies of TAE regimens?
   A. A 12-week extension interval is feasible only when using aflibercept
   B. The majority of eyes that experience fluid recurrence can subsequently be successfully rechallenged when treated according to the previously identified maximum between-visit interval
   C. VA gains achieved after the induction phase can be maintained for 7 years
   D. Visual outcomes were similar after 2 years in patients treated with monthly or TAE dosing regimens
5. A patient with neovascular AMD responds to initial treatment with 3 monthly injections of bevacizumab, with improvement on OCT and in VA, and is switched to a TAE regimen. After 3 years, the patient shows loss of vision at 2 consecutive visits while being maintained on an 8-week injection interval, but there is no evidence of fluid recurrence on OCT and no non-AMD pathology to explain the decreased vision. What is your next step?
   A. Decrease the injection interval by 2 weeks
   B. Evaluate the patient with FAF to check for GA
   C. Stop treating
   D. Suspect tachyphylaxis and switch anti-VEGF agents
6. A patient with neovascular AMD is being maintained on a TAE regimen with ranibizumab every 7 weeks for 2 years. On presentation at his next scheduled visit, he is found to have recurrence of fluid with a small loss of vision. What is your next step?
   A. Re-treat and have the patient return again at 6 weeks to see if the fluid persists
   B. Review the OCT carefully to see if the fluid is explained by some other pathology
   C. Switch to bevacizumab because it is associated with better drying of the macula
   D. Tell the patient that he will need to be maintained on fixed monthly injections
7. Which of the following statements is true regarding outcomes after 1 year in the PLANET study of treatment for PCV?
   A. Aflibercept monotherapy was noninferior to aflibercept plus PDT for mean BCVA improvement
   B. Aflibercept monotherapy was superior to aflibercept plus PDT for mean BCVA improvement
   C. The complete polyp regression rate was significantly higher in eyes treated with aflibercept plus PDT than in eyes treated with aflibercept monotherapy
   D. The complete polyp regression rate was numerically higher in eyes treated with aflibercept monotherapy than in eyes treated with aflibercept plus PDT, but the difference was not statistically significant
8. Brolucizumab and abicipar pegol are investigational agents for neovascular AMD that act by inhibiting:
   A. Angiopoietin-2
   B. Integrin
   C. Tissue factor
   D. VEGF